Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to sift through Kodiak Sciences鈥� dense clinical disclosures and R&D spend tables? Biotech filings often exceed 300 pages, and Kodiak鈥檚 reports add layers of trial protocols, antibody-biopolymer data, and cash-runway projections that can overwhelm even seasoned analysts.
Stock Titan solves that problem. Our AI instantly converts each Kodiak Sciences quarterly earnings report 10-Q filing and Kodiak Sciences annual report 10-K simplified into plain-English highlights鈥攕o you can see burn-rate trends, pivotal study costs, and ABC platform milestones without hunting through footnotes. AG真人官方-time alerts flag every Kodiak Sciences 8-K material events explained, while live dashboards surface Kodiak Sciences insider trading Form 4 transactions the moment they hit EDGAR. Need context? Click once to read understanding Kodiak Sciences SEC documents with AI summaries that explain why each metric matters.
Whether you鈥檙e tracking Kodiak Sciences executive stock transactions Form 4 before Phase 3 data, comparing segment R&D lines across quarters, or verifying board pay in the latest Kodiak Sciences proxy statement executive compensation, you鈥檒l find everything here: 10-Ks, 10-Qs, 8-Ks, S-3 dilution filings, and more. Investors use our platform to:
- Watch Kodiak Sciences Form 4 insider transactions real-time for sentiment shifts
- Download AI-tagged exhibits from every filing
- Access concise Kodiak Sciences earnings report filing analysis within minutes of release
No more wading through technical jargon鈥攐ur expert-trained AI distills what matters so you can act faster on Kodiak鈥檚 next breakthrough.
Kodiak Sciences Inc. (KOD) reported continued clinical progress alongside significant cash burn and liquidity concerns. For the six months ended June 30, 2025 the company recorded a net loss of $111.8 million and used $63.8 million of cash in operations. The company reported $104.2 million of cash and cash equivalents as of June 30, 2025 (and $110.349 million including restricted cash), an accumulated deficit of $1,440,512 (amounts presented in thousands) and a $100,000 liability related to the sale of future royalties. Management states there is substantial doubt about the company鈥檚 ability to continue as a going concern and plans to seek additional financing.
Operationally, Kodiak is advancing multiple late-stage programs. GLOW2 enrollment is complete (more than 250 patients) with topline data expected 1Q 2026; DAYBREAK (tarcocimab and KSI-501) remains actively enrolling with topline data expected 3Q 2026 and the company intends to seek a single BLA in 2026 following these results. KSI-101 completed Phase 1b APEX with selected doses moving into Phase 3 PEAK and PINNACLE, which are actively enrolling. The company recognized a $1.9 million non-cash lease impairment tied to a sublease and recorded sublease income in 2025. Research and development expense rose materially to $86.4 million for the six months ended June 30, 2025, reflecting expanded pivotal trials and manufacturing work.
Kodiak Sciences Inc. disclosed in a Form 8-K dated August 13, 2025 that it published a press release reporting the company鈥檚 financial results for the quarter ended June 30, 2025 and related business highlights; that press release is attached as Exhibit 99.1 to this report.
The filing states the press release and information contained or incorporated herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by specific reference. The 8-K lists an Inline XBRL cover page as Exhibit 104 and is signed by Victor Perlroth, M.D., Chief Executive Officer. The company鈥檚 common stock trades under the ticker KOD on The Nasdaq Stock Market.
FAQ
What is the current stock price of Kodiak Sciences (KOD)?
What is the market cap of Kodiak Sciences (KOD)?
